Lapatinib ( DrugBank: Lapatinib )

3 diseases

34. 神経線維腫症

臨床試験数 : 137 / 薬物数 : 213 - (DrugBank : 76) / 標的遺伝子数 : 87 - 標的パスウェイ数 : 200

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00973739 (ClinicalTrials.gov)	September 2009	3/9/2009	Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors	Phase II Study of Lapatinibin Children and Adults With Neurofibromatosis Type 2(NF2) and NF2-related ...	Neurofibromatosis 2;Vestibular Schwannoma	Drug: Lapatinib	New York University School of Medicine	GlaxoSmithKline	Completed	4 Years	80 Years	All	21	Phase 2	United States
2	NCT00863122 (ClinicalTrials.gov)	June 2009	13/3/2009	Concentration and Activity of Lapatinib in Vestibular Schwannomas	Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinibin Vivo in Vestibu ...	Vestibular Schwannoma;NF2;Neurofibromatosis 2;Acoustic Neuroma;Auditory Tumor	Drug: lapatinib	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	The Children's Tumor Foundation;GlaxoSmithKline;New York University;Ohio State University;House Rese ...	Completed	18 Years	N/A	All	26	Early Phase 1	United States

臨床試験数 : 18 / 薬物数 : 33 - (DrugBank : 10) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 65

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00939523 (ClinicalTrials.gov)	July 2009	14/7/2009	Targeted Therapy With Lapatinibin Patients With Recurrent Pituitary Tumors Resistant to Standard The ...	Targeted Therapy With Lapatinibin Patients With Recurrent Pituitary Tumors Resistant to Standard The ...	Pituitary Adenomas;Prolactinomas	Drug: Lapatinib	Cedars-Sinai Medical Center	NULL	Completed	18 Years	N/A	All	9	Phase 2	United States

臨床試験数 : 203 / 薬物数 : 191 - (DrugBank : 51) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 128

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-OPC-17011664	2017-08-01	2017-06-14	A single center clinical study of EGFR/HER2 targeted inhibitor Lapatinibin the treatment of refracto ...	A single center clinical study of EGFR/HER2 targeted inhibitor Lapatinibin the treatment of refracto ...	Pituitary ACTH-secreting adenoma	Treatment group:lapatinib;	Peking Union Medical College Hospital	NULL	Pending	18	75	Both	Treatment group:30;		China